| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10792271 | HARROW EYE | Topical formulations of chloroprocaine and methods of using same |
Sep, 2038
(14 years from now) | |
Iheezo is owned by Harrow Eye.
Iheezo contains Chloroprocaine Hydrochloride.
Iheezo has a total of 1 drug patent out of which 0 drug patents have expired.
Iheezo was authorised for market use on 27 September, 2022.
Iheezo is available in gel;ophthalmic dosage forms.
Iheezo can be used as method of inducing ocular anesthesia.
The generics of Iheezo are possible to be released after 15 September, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 27, 2025 |
Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 September, 2022
Treatment: Method of inducing ocular anesthesia
Dosage: GEL;OPHTHALMIC
More Information on Dosage
IHEEZO family patents
